Summary
Defects in cytochrome oxidase (CO; complex 4) have recently been demonstrated in blood platelets and in brain tissue from patients with Alzheimer's disease (AD) with possible etiological implications. Because of pathogenetic similarities with AD, we have measured the activities of several mitochondrially localised enzymes in the blood platelets of individuals afflicted with trisomy-21 (Down's syndrome). The activities of monoamine oxidase, cytochrome oxidase, isocitrate dehydrogenase, and glutamate dehydrogenase were assayed in washed platelets from sixty caucasian, male and female control individuals (ages 18–60) and ten, young Down's Syndrome patients (ages 9–21). Significant reductions in the activities of monoamine oxidase, cytochrome oxidase, and isocitrate dehydrogenase were found. In all cases the average activities in Down's syndrome individuals were approximately two-thirds those of controls (DS/Controls=0.68, 0.67, 0.64 respectively). The activity of the fourth enzyme studied, glutamate dehydrogenase, was found to be similar to controls. Results suggest that these reductions are a consequence of a generalised mitochondrial disturbance which may lie behind some pathogenetic aspect(s) of the disease.
Similar content being viewed by others
References
Beal MF (1992) Mechanisms of exitotoxicity in neurologic diseases. FASEB J 6(15): 3338–3344
Beal MF, Hyman T, Koroshetz W (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative disease? TINS 16(4): 125–131
Bennett M, Diamond D, Stryker S, Parks J (1992) Cytochrome oxidase inhibition: a novel animal model for Alzheimer's disease. J Ger Psych Neurol 5(2): 93–101
Bloem B, Irwin I, Buruma D, Hann J, Roos R, Tetrud J, Langston J (1990) The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci 97(2–3): 273–293
Connor J, Tucker P, Johnson M, Snyder B (1993) Cerulopasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci Lett 159: 88–90
Fowler CJ, Wiberg Å, Gustacsson KH, Winblad B (1981) Platelet monoamine oxidase activity in Down's syndrome. Clin Genet 19: 307–311
Frim D, Simpson J, Uhier T, Short P, Bossi S, Breakefield X, Isacson O (1993) Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J Neurosci Res 35: 452–458
Gershoff SN, Hegsted DM, Trulson MF (1958) Metabolic studies of mongoloids. Am J Clin Nutr 6: 526–532
Groner Y, Elroy-Stein O, Avraham KB, Yarom R, Schickler M, Knobler H, Rothman G (1990) Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene. J Physiol (Paris) 84: 53–77
Holtzman D, Li Y, Chen K, Gage F (1993) Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age related neurodegeneration. Neurology 43: 2668–2673
Hyman BT (1992) Down's syndrome and Alzheimer's disease. Prog Clin Biol Res 379: 123–142
Ikebe S, Tanaka M, Ohno K, Sato W, Hattori K, Kondo T, Mizuno Y, Ozawa T (1990) Increase in deleted mitochondrial DNA in the striatum in Parkinson's disease. Biochem Biophys Res Commun 170: 1044–1048
Kadenbach B, Muller-Hockner J (1990) Mutations of mitochondrial DNA and human death. Naturwissenschaften 77(5): 221–225
Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM (1992) Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59: 776–779
Klinteberg B, Hallman J, Oreland L, Wrisén A, Levander SE, Schalling D (1992) Exploring the connections between platelet MAO activity and behavior II. Impulsive personality without neuropsycholobcal signs of disinhibition in air force pilot recruits. Neuropsychobiology 26: 136–145
Lake CR, Ziegler MG, Coleman M (1979) Evaluation of the sympathetic nervous system in trisomy 21 (Down's syndorme). J Psychiat Res 15: 1–6
Linnane A, Marzuki S, Ozawa T, Tanaka M (1989) Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet i: 642–645
Lott IT, Chase TN, Murphy DL (1972) Down's syndrome: transport, storage, and metabolism of serotonin in blood platelets. Ped Res 6: 730–735
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Malamud N (1972) Neuropathology of organic brain syndromes associated with aging. Adv Behav Biol 3: 63–87
Markwell MAC, Maas SM, Biebar LL, Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and in protein samples. Anal Biochem 87: 206–210
More R, Amir N, Meyer S, Kopolovic J, Yarom R (1982) Platelet abnormalities in Down's syndrome. Clin Genet 22: 128–136
Parker WD, Filley CM, Parks JK (1990a) Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40: 1302–1303
Parker WD, Boyson S, Luder A, Parks J (1990b) Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 40: 1231–1234
Rand ML, Greenberg JP, Packham MA, Mustard JF (1981) Density subpopulations of rabbit platelets: size, protein, and sialic acid content, and specific radioactivity changes following labeling with35S-sulphate in vivo. Blood 57: 741–746
Rosner F, Ong BF (1965) Blood serotonin activity in trisonomic and dislocation Down's syndrome. Lancet i: 1191–1193
Schmidt E (1974) Glutamate dehydrogenase UV-assay. In: Bergmeyer HU (ed) Methods of enzymatic analysis, vol 2. Academic Press, NY, pp 650–656
Simonian N, Hyman T (1993) Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 52(6): 580–585
Smith L (1955) Spectrophotometric assay fo cytochrome oxidase. In: Glich D (ed) Methods of biochemical analysis, vol II. Interscience, NY, pp 427–434
Van Zuylen AJ, Bosman GJ, Ruitenbeek W (1992) No evidence for reduced thrombocyte cytochrome oxidase activity in Alzheimer's disease. Neurology 42: 1246
Wetterberg L, Gustavson KH (1972) Low dopamine β-hydroxylase activity in Down's syndrome. Clin Genet 3: 152–153
Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17(3): 278–282
Wolfson SK, Willams-Ashman HG (1957) Isocitric and phosphogluconic dehydrogenases in human serum blood. Proc Exp Biol Med 96: 231–234
Yates CM, Simpson J, Gordon A (1986) Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. Neurosci Lett 65: 189–192
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prince, J., Jia, S., Båve, U. et al. Mitochondrial enzyme deficiencies in Down's syndrome. J Neural Transm Gen Sect 8, 171–181 (1994). https://doi.org/10.1007/BF02260938
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260938